N. Junjie*a (Dr)

a First People's Hospital of Zigong City, Sichuan Province, Zigong 643000, China, Zigong, CHINA

* 196425984@qq.com

Objective To optimize the oxygen therapy regimen for infants with pulmonary disease undergoing bronchoscopy. Methods A total of 42 children were divided into nasal cannula oxygen (NC) group and modified T-piece resuscitator (TPR) group. TPR group: The TPR was connected to the air-oxygen mixer for respiratory support, and the oxygen concentration was set to 29%; the initial flow rates were: 5L/min, 6L/min, and the corresponding weight ranges were: 4-8 kg, 8-10kg; set PEEP to 5cmH20; PIP to 20cmH20. NC group: 2L/min of oxygen. The results of blood oxygen saturation in the two groups were recorded as the main index (judgment criteria: SpO2<90% was hypoxemia, of which 85%≤SpO2<90% was mild hypoxia, and 80%≤SpO2<85% was moderate hypoxia , SpO2<80% was severe hypoxia), and the heart rate and breathing rate during the operation were recorded as secondary indicators (judgment criteria: bradycardia <P5, tachycardia >P95, bradypnea <P5, apnea> 20s or shortness of breath > P95). Results 1. Each group was assigned 21 patients, and the baseline characteristics were not statistically significant; 2. The incidence of hypoxemia in the TPR group was significantly lower than that in the NC group (χ2= 6.46, P=0.011); the incidence of mild hypoxemia in TPR group was higher than that in NC group, but the incidence of severe hypoxemia in infants was significantly lower than that in NC group(Z=2.52, P=0.012); 3. The incidence of intraoperative arrhythmia and respiratory rhythm abnormality in the NC group was significantly higher than that in the TPR group (χ2=2.74 and 8.40, P<0.05). Conclusion The modified TPR can significantly reduce the incidence of hypoxia in infants with lung diseases receiving FB. The risk of oxygenemia; compared with traditional nasal cannula oxygen, TPR can significantly improve the severity of hypoxemia, and reduce the incidence of arrhythmia and respiratory rhythm abnormalities.

Disclosure of funding source(s): none